Key result
Oral anticoagulation in atrial fibrillation patients with a CHA2DS2-VASc score of 1 due to hypertension requires careful consideration of competing ischemic stroke and hemorrhage risks.
Why the study?
Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?
Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?
Highlights the clinical dilemma of optimal antithrombotic management in atrial fibrillation patients with a CHA2DS2-VASc score of 1 due solely to hypertension.
Optimal antithrombotic strategy remains uncertain in AF with CHA2DS2-VASc score 1 from hypertension; leaves open need for targeted trials.
-VASc score of 1 are considered to be low risk and may be not expected to benefit from anticoagulation therapy. Hypertension carries an increased risk of ischemic stroke, however, it is also a clear risk factor for hemorrhage in AF. Therefore, the optimal antithrombotic management is highlighted in patients with AF with only one risk factor especially hypertension.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) studied this question. Oral anticoagulation in atrial fibrillation patients with a CHA2DS2-VASc score of 1 due to hypertension requires careful consideration of competing ischemic stroke and hemorrhage risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: